TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04815798

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bacteriophage-loaded Microcapsule Spray
Description: Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages encapsulated in a biodegradable polymer. This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention consists of a dosage-metered airless spray containing a buffer solution analogous to the study intervention. This placebo will be delivered topically every 3 days for 56 days or until wound has healed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.
Study: NCT06350448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Washed Microbiota Transplantation
Description: Washed microbiota suspension (5U) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5U, three times.
Study: NCT04753489

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban film-coated tablet 10 mg
Description: Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of rivaroxaban.

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban film-coated tablet 10 mg
Description: Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of rivaroxaban.

Intervention type: DRUG
Group type: OTHER
Intervention: Xarelto® film-coated tablet 10 mg
Description: Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 10 mg of rivaroxaban.

Intervention type: DRUG
Group type: OTHER
Intervention: Xarelto® film-coated tablet 10 mg
Description: Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 10 mg of rivaroxaban.
Study: NCT04283656

Intervention type: DRUG
Group type: OTHER
Intervention: Doravirine/Lamivudine/Tenofovir
Description: 100mg/300mg/300mg orally for one dose, daily

Intervention type: DRUG
Group type: OTHER
Intervention: Doravirine/Lamivudine/Tenofovir
Description: 100mg/300mg/300mg orally for one dose, daily

Intervention type: DRUG
Group type: OTHER
Intervention: Spironolactone 100mg
Description: 200mg orally for two doses, twice-daily

Intervention type: DRUG
Group type: OTHER
Intervention: Spironolactone 100mg
Description: 200mg orally for two doses, twice-daily

Intervention type: DRUG
Group type: OTHER
Intervention: Spironolactone 100mg
Description: 200mg orally for two doses, twice-daily

Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol 2mg
Description: 4mg orally for two doses, twice-daily
Study: NCT05399550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: Intravenous Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Intravenous Solution
Study: NCT04283656

Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol 2mg
Description: 4mg orally for two doses, twice-daily

Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol 2mg
Description: 4mg orally for two doses, twice-daily

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo for one dose, daily
Study: NCT05269550

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Intermediate Risk Patients
Description: Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Six months of androgen deprivation therapy will commence with the start of radiotherapy (concurrent plus adjuvant)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Risk or Very High-Risk Patients
Description: Patients will receive 35Gy/5 fractions to the whole prostate (25Gy to whole Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Pelvic lymph nodes will receive 25Gy/5 fractions synchronous with prostate treatment with a simultaneous boost to imaging involved nodes to a maximum of 35Gy/5 fractions. Eighteen months of androgen deprivation therapy will commence with the start of radiotherapy (concurrent plus adjuvant)
Study: NCT05380349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combinations of up to 3 FDA approved drugs from a panel of compounds
Description: personalized drug combinations
Study: NCT05931185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low frequency transcutaneous electrical stimulation and Therapeutic Ultrasound
Description: patients will receive low-frequency transcutaneous electrical stimulation for 15 minutes and therapeutic Ultrasound for 10 minutes as a treatment and patients will receive a total of 12 treatment sessions (3 sessions per week for 4 weeks and then follow-up will be done for the next 2 weeks) and the total duration of each session will be of 25 minutes.
Study: NCT05882396

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rood's approach
Description: Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.
Study: NCT05021952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth App and wearable device
Description: An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
Study: NCT06353503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow aspirate concentrate
Description: local knee joint injection of autologous bone marrow
Study: NCT05305924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant Run-In
Description: The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
Study: NCT05931185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Ultrasound
Description: patients will receive a therapeutic ultrasound for 10 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency transcutaneous electrical stimulation
Description: participants will receive low-frequency transcutaneous electrical stimulation for 15 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
Study: NCT05053126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg
Description: Participant will receive an oral dose of pregabalin 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin 450 mg
Description: Participant will receive an oral dose of pregabalin 450 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg with oxycodone 20 mg
Description: Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin 450 mg with oxycodone 20 mg
Description: Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone 20 mg
Description: Participant will receive an oral dose of oxycodone 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant will receive an oral dose of placebo
Study: NCT04873869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-921352
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06374862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization
Description: specific mobilization on neuromuscular functioning, thanks to surface EMG, before and after a specific mobilization of the spine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: no effect
Description: a mobilization identified as no effect could modulate neuromuscular activity by a placebo effect.
Study: NCT06334172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin
Study: NCT05350475

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton therapy
Description: Patients in the experimental arm will receive proton therapy within the same dose and fraction schedule as patients receiving photon therapy, which is standard treatment.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon therapy
Description: Patients in the photon arm will receive standard treatment with photon therapy.
Study: NCT06311617

Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus photography and optical coherence tomography
Description: Non-mydriatic fundus photography and optical coherence tomography will be performed at 3 timepoints

Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus photography and optical coherence tomography
Description: Non-mydriatic fundus photography and optical coherence tomography will be performed at 3 timepoints

Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus photography and optical coherence tomography
Description: Non-mydriatic fundus photography and optical coherence tomography will be performed at 3 timepoints
Study: NCT05231824

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Treatment
Description: Behavioral weight loss treatment is the current gold standard treatment for obesity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-optimized Behavioral Weight Loss Treatment
Description: AI-optimized Behavioral Weight Loss Treatment will continuously vary intensity (automated text message, videoconference group, individual coaching call) and coach type (paraprofessional or MS-level expert) based on continuously-monitored participant digital data.
Study: NCT05180513

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teleconference Mindfulness Intervention
Description: The teleconference intervention is administered by a trained interventionist via Zoom and is based on a manual adapted from a traditional MBSR version. Practices and activities include meditations, mindful breathing exercises and movements, discussions, and reflections, which participants learn at weekly sessions and practice on their own throughout the week. To adapt the traditional MBSR program for the target community population, intervention materials were reviewed for feedback from community stakeholders, and modified according to their feedback.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smartphone App Mindfulness Intervention
Description: The smartphone app intervention is administered through the app. The smartphone app aligns with the traditional MBSR format, but training and practice is done individually and independently by members of this group. To adapt the traditional MBSR program for the target community population, the app was tested by community stakeholders and modified according to their feedback.
Study: NCT05987982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral exercises and oral hygiene
Description: The patients will be required to perform oral exercises and maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral care
Description: The patients will be required to maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
Study: NCT06315192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke Alarm
Description: Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.
Study: NCT06461039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111 A
Description: NNC0487-0111 A will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111 C
Description: NNC0487-0111 C will be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)
Description: Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) will be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen - 500 mg/15 ml
Description: Acetaminophen - 500 mg/15 ml will be taken orally.
Study: NCT06334172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT04717076

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: App-based nutritional concept and fitness tracking
Description: The App-based nutritional concept based on menu plan, which are personalized according to participants age, gender, physical activity. The App is coupled with a Smartwatch to encourage and track physical activity over the study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional concept with individual nutritional counselling
Description: Nutritional concept based on personalized menu plans and individual nutritional counselling every four weeks (4 times during the study)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional concept without individual nutritional counselling
Description: Nutritional concept based on personalized menu plans
Study: NCT05875558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-TACE
Description: Lipiodol combined with microspheres
Study: NCT05187702

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional exersize
Description: Participants will be given balance and strengthening exercises covering the balance exercise protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional exersize
Description: Participants will be given balance and strengthening exercises covering the balance exercise protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exersize
Description: 60% of the maximum heart rate is given 3 walking eccentricity per week
Study: NCT00753818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DHA and ARA
Description: various levels of DHA and ARA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DHA and ARA
Description: various levels of DHA and ARA
Study: NCT05260749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: real-time fMRI neurofeedback training procedure
Description: real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
Study: NCT05146440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM14
Description: Pharmaceutical form: PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety.~Route of administration: PM14 drug product was developed for administration by the i.v. route. Before use, the vials are reconstituted with 10 mL of sodium chloride 9 mg/mL (0.9%) solution for infusion to give a solution containing 0.5 mg/mL of PM14. Prior to administration, the reconstituted DP solution should be further diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. Each vial of PM14 5.0 mg is a single use vial.
Study: NCT04441008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated Intermittent Theta Burst (aiTBS)
Description: High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Description: ECT as per standard clinical care and management.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Description: ECT as per standard clinical care and management.
Study: NCT00753818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DHA and ARA
Description: various levels of DHA and ARA

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study: NCT06425770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indirect digital impression and 3D printed cast
Description: the provisional restoration will be scanned with intraoral scanner extraorally, based on which a virtual model will be created, from which a 3D printed cast will be created with manually fabricated gingival mask based on the provisional restoration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct digital impression
Description: the emergence profile will be directly scanned with intraoral scanner at 0, 2, 10, and 20 minutes after removing the provisional restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional impresion and cast
Description: conventional impression with elastomer (silicon), from which a high-precision epoxi-resin cast with gingival mask will be created
Study: NCT05620602

Intervention type: OTHER
Intervention: Remedial treatment within 3 months
Description: The interval between the time of this treatment and the last day of the last therapy is within 3 months.Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d.

Intervention type: OTHER
Intervention: Remedial treatment within 3 to 6 months
Description: The interval between the time of this treatment and the last day of the last therapy is 3-6 months.~Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d.

Intervention type: OTHER
Intervention: Remedial treatment within 6 to 12 months
Description: The interval between the time of this treatment and the last day of the last therapy is 6-12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d.

Intervention type: OTHER
Intervention: Remedial treatment after 12 months
Description: The interval between the time of this treatment and the last day of the last therapy is more than 12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d.
Study: NCT06131827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: Neural mobilization will be performed with twenty oscillations per minute being repeated three sets of one minute respecting one minute interval of rest between each set for 4 days weekly for six week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task based activities
Description: Task based activities consisted of different types task which will be performed with the dosage of 45 minute session 5 days weekly for six week.
Study: NCT06034522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adipearl
Description: Injection of the investigational device in the face.
Study: NCT04847414

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1C, other investigations
Description: we will do some necessary investigations for prospective group
Study: NCT05709977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Fixed set of acupuncture points

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine nasal spray
Description: Carelastin® (1 mg/ml) azelastine nasal spray
Study: NCT05367726

Intervention type: OTHER
Intervention: patients having had skin coverage of the knee
Description: the cutaneous cover is not always optimal to protect the prosthesis, an act of reconstructive plastic surgery is then necessary